固定式与可调式重力分流阀在两种不同临床环境中的适用性
这项回顾性双中心队列研究评估重力分流阀在两种临床环境中的效用:在Rigshospitalet,22例复杂分流史患者在外科翻修术中接受proGAV®和proSA®分流系统,比较植入前后随访期的临床结局;在Aarhus大学医院,98例接受重力阀(proGAV®联合固定式SA®或可调式proSA®)的患者与90例非重力阀患者比较2年随访结局。结果显示复杂患者植入后每年约避免两次外科翻修(p 0.031)和两次住院(p 0.009),而广泛患者中结局参数与分流存活率变化稳定或无统计学显著性。作者认为重力阀安全有用,可作为广泛患者的一线等效替代选择,proSA®阀应考虑用于复杂分流患者。
要点
- Rigshospitalet 22例复杂分流史患者植入proGAV®和proSA®后,每年约避免两次外科翻修(p 0.031)和两次住院(p 0.009)。
- Aarhus大学医院98例重力阀与90例非重力阀患者相比,临床结局参数变化和分流存活率稳定或无统计学显著性。
- 作者认为重力阀安全有用,可作为广泛患者的一线等效替代选择,proSA®阀应考虑用于复杂分流患者。
核心结论
- 重力阀在临床实践中安全有用,可作为广泛患者的一线等效替代分流阀,proSA®阀应考虑用于复杂分流患者。
研究设计与样本
- 回顾性双中心队列研究,由两种不同的分流管理策略构成。
- Rigshospitalet纳入22例复杂分流史并接受proGAV®和proSA®分流系统外科翻修的患者,比较植入前后随访期临床结局。
- Aarhus大学医院纳入90例非重力阀患者和98例重力阀患者(proGAV®联合固定式SA®或可调式proSA®),比较2年随访临床结局。
主要发现
- Rigshospitalet患者proGAV®和proSA®植入前、后平均随访时间分别为2.3年和1.5年。
- Rigshospitalet每例患者植入proGAV®和proSA®后每年约避免两次外科翻修(p 0.031)和两次住院(p 0.009)。
- Aarhus大学医院重力阀组与非重力阀组相比,临床结局参数变化和分流存活率稳定或无统计学显著性。
临床怎么用
- 作者认为重力阀安全有用,可作为广泛患者的一线等效替代分流阀。
- 作者认为proSA®阀应考虑用于复杂分流患者。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Gravitational shunt valves and most recently the adjustable proSA® gravitational valve have been designed to counteract overdrainage and thereby improving clinical outcome. So far, the applicability in a broader mix of hydrocephalus patients is unrevealed. The aim of this study was to evaluate the utility of gravitational valves in two different clinical settings. METHODS: This retrospective double-center cohort study was enabled by two different shunt management policies. At Rigshospitalet, patients with a complicated shunt history receiving a proGAV® and proSA® shunt system during surgical revision were included, and clinical outcome in the follow-up periods before and after was compared. At Aarhus University Hospital, a combination of a proGAV® and a fixed (SA®) or adjustable (proSA®) gravitational valve was used in all shunt procedures. Clinical outcome in a 2-year follow-up period was compared to a cohort receiving non-gravitational valves in the period before the transition to gravitational valves. RESULTS: Twenty-two patients were included at Rigshospitalet. Mean follow-up time before and after proGAV® and proSA® implantation was 2.3 and 1.5 years, respectively. In each patient, roughly two surgical revisions (p 0.031) and two hospitalizations (p 0.009) were avoided each year after proGAV® and proSA® implantation. At Aarhus University Hospital, 90 patients with non-gravitational valves and 98 patients with gravitational valves were included. Changes in clinical outcome parameters and shunt survivals were either stable or statistically insignificant. CONCLUSIONS: Gravitational valves are safe and useful in clinical practice and represent an equivalent alternative as a first-line shunt valve in a broad mix of patients, while proSA® valves should be considered for complex shunt patients.
引用
- Månsson PK, Hansen TS, Juhler M, et al. The applicability of fixed and adjustable gravitational shunt valves in two different clinical settings. Acta Neurochir (Wien). 2018. PMID: 29804178. doi:10.1007/s00701-018-3568-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。